ESMO Congress 2022: Abstracts

The abstract submission system is closed

Abstract submission deadlines

Outcome notifications

Outcome notifications are expected to be made available to first authors by mid-July 2022.

Abstract submission categories

*Abstracts may also be submitted to the Cancer nursing track. Submissions in these categories will be reviewed by the European Oncology Nursing Society (EONS) Scientific Committee for selection and presentation in the EONS cancer nursing programme. Unless otherwise stated, submissions in the Cancer nursing categories must follow all regular ESMO 2022 submission regulations and guidelines.

Late-breaking abstracts (LBA)

Late-breaking abstracts may be submitted for high quality, new research findings from randomised phase II or phase III trials with implications for clinical practice or understanding of disease processes.

The work must not have been previously published in any publication in a peer review setting or presented at a meeting of any other scientific organisation prior to the ESMO 2022.

Submitters of preliminary versions receiving approval to proceed must submit the final LBA by 9 August 2022, 21:00 CEST (Central European Summer Time).

Trial in progress abstracts (TiP)

Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to ESMO 2022.

It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis and consequently will only require the completion of two (2) sections:

• Background
• Trial design

Please note:

• Recruitment must have already begun or have been completed by the abstract submission deadline of 3 May 2022.
• Abstracts including results or preliminary data will be rejected.
• Trial in Progress abstracts can be accepted for Poster presentation only.
• Encore TiP abstracts will not be accepted.

Publication schedule of accepted abstracts

1. All regular abstracts accepted for presentation at ESMO 2022 as Proffered Paper (suffix O), Mini Oral (suffix MO), Poster (suffix P or TiP) will be published online via the ESMO website at 00:05 CEST on Monday, 5 September 2022.
2. All Late-breaking abstracts accepted for presentation at ESMO 2022 as Proffered Paper or Mini Oral (prefix LBA) will be published online via the ESMO website at 00:05 CEST on Thursday, 8 September 2022.
3. LBA1 and Abstract 903O will be published online via the ESMO website at 00:05 CEST on Friday, 9 September 2022.
4. LBA10 will be published online via the ESMO website at 00:05 CEST on Monday, 12 September 2022.

Embargo policy

Data and information included in accepted abstracts is under embargo until the relevant embargo release date cited in the schedule above.

Data and information beyond what is included in all accepted abstracts, for example full data sets, may only be made public at the start of the official programme session during which the study is presented.

Presentation of accepted abstracts

 The ESMO 2022 Scientific Committee will select abstracts for presentation during the Congress based on the following possibilities:

• Presidential Symposium – Oral presentations by authors presenting cutting-edge and significant clinical practice-changing studies, followed by expert discussion and perspectives.
• Proffered Paper – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
• Mini Oral – Short oral presentations by authors presenting data of good quality, followed by expert discussion and perspectives.
• Poster – Display session for review, discussion and questions. The presenting authors must be available for Q&A to represent their work.

All accepted abstracts, including late-breaking abstracts, will be published online only in the ESMO 2022 Abstract Book, a supplement to the official ESMO journal, Annals of Oncology.